Workflow
Cogent Biosciences(COGT)
icon
搜索文档
Cogent Biosciences (COGT) Presents At SVB Leerink 10th Annual Global Healthcare Conference - Slideshow
2021-02-28 17:36
Developing Precision therapies for genetically defined diseases Corporate Presentation Q1 2021 | --- ...
Cogent Biosciences(COGT) - 2020 Q3 - Quarterly Report
2020-11-10 06:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 Par Value COGT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...
Cogent Biosciences(COGT) - 2020 Q2 - Quarterly Report
2020-08-12 05:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 Par Value UMRX The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission ...
Cogent Biosciences(COGT) - 2020 Q1 - Quarterly Report
2020-05-12 04:53
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 Par Value UMRX The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio ...
Cogent Biosciences(COGT) - 2019 Q4 - Annual Report
2020-03-27 04:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38443 UNUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 46-5308248 (State or other jurisdiction ...
Unum Therapeutics (UMRX) Investor Presentation - Slideshow
2020-03-05 19:57
| --- | --- | --- | --- | |------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Delivering novel cell therapies to cure cancer | | | | | CORPORATE PRESENTATION MARCH 2020 | | | | Forward-Looking Statements and Risk Factors This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ ...
Unum Therapeutics (UMRX) Investor Presentation - Slideshow
2019-12-07 00:37
UNUM THERAPEUTICS CORPORATE PRESENTATION DECEMBER 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed forward-looking ...
Cogent Biosciences(COGT) - 2019 Q3 - Quarterly Report
2019-11-13 05:49
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | |------------------------------------------------------------------------------------------------------------------------------|----------- ...
Unum Therapeutics (UMRX) Investor Presentation - Slideshow
2019-09-17 01:31
UNUM THERAPEUTICS CORPORATE PRESENTATION SEPTEMBER 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed forward-lookin ...
Unum Therapeutics (UMRX) Presents At Wedbush PacGrow Healthcare Conference - Slideshow
2019-08-16 02:30
UNUM THERAPEUTICS WEDBUSH PACGROW HEALTHCARE CONFERENCE AUGUST 2019 FORWARD-LOOKING STATEMENTS AND RISK FACTORS This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward looking statements. All statements other than statements of historical fact could be deemed fo ...